Effect of natural HIV-1 envelope V1-V2 sequence diversity on the binding of V3-specific and non-V3-specific antibodies

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 16, Issue 2, 1997, Pages 69-73

  Rencher, Samantha D ^a,b   Hurwitz, Julia L ^a,b,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF MEMPHIS   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

ELISA; HIV 1 envelope; Monoclonal antibody; Variable regions

Indexed keywords

CHIMERIC PROTEIN; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; ANTIGEN BINDING; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VACCINIA VIRUS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; VACCINIA; VACCINIA VIRUS;

EID: 0030725907     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199710010-00001     Document Type: Article

References (35)

1. Javaherian K, Langlois AJ, McDanal C, et al. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci USA 1989;86:6768-72.
2. Profy AT, Salinas PA, Eckler LI, Dunlop NM, Nara PL, Putney SD. Epitopes recognized by the neutralizing antibodies of an HIV-1-infected individual. J Immunol 1990;144:4641-7.
3. Burns DPW, Desrosiers RC. Envelope sequence variation, neutralizing antibodies and primate lentivirus persistence. Curr Top Microbiol Immunol 1994;188:185-219.
4. Steimer KS, Sakamoto D, Sun YD, West D, Baenziger J, Sinangil F. Primary isolate neutralizing activity of human antibodies directed to recombinant, native HIV-SF2 GP120 (rgp120-SF2). J Cell Biochem 1994;(Suppl 18B):114.
5. Posner MR, Hideshima T, Cannon T, Mukherjee M, Mayer KH, Byrn RA. An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection. J Immunol 1991;146:4325-32.
6. Burton DR, Pyati J, Koduri R, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994;266:1024-7.
7. White-Scharf ME, Potts BJ, Smith LM, Sokolowski KA, Rusche JR, Silver S. Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization. Virology 1993;192:197-206.
8. Marasco WA, Bagley J, Posner M, et al. Molecular characterization of a panel of HIV-1 broadly neutralizing, CD4 binding site directed human anti-gp120 monoclonal antibodies (Mabs). International Conference on AIDS, 1992, Abstract #MoA0046:Mo13.
9. Sullivan N, Thali M, Furman C, Ho DD, Sodrosk, J. Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody. J Virol 1993;67:3674-9.
10. Wyatt R, Moore J, Accola M, Desjardin E, Robinson J, Sodroski J. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol 1995;69:5723-33.
11. Ryan KW, Owens RJ, Hurwitz JL. Preparation and use of vaccinia virus vectors for HIV protein expression and immunization. In: Lefkovits I, ed. Immunology methods manual. London: Academic Press, 1997:1995-2015.
12. Slobod KS, Rencher SD, Farmer A, Smith FS, Hurwitz JL. HIV type 1 envelope sequence diversity in an inner city community. AIDS Res Hum Retroviruses 1994;10:873-5.
13. Ratner L, Haseltine W, Patarca R, et al. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 1985;313:277-84
14. Srinivas RV, Hurwitz JL. HIV growth, measurement and neutralization. In: Lefkovits I, ed. Immunology methods manual. London: Academic Press, 1997:1961-73.
15. Prince AM, Reesink H, Pascual D, et al. Prevention of HIV infection by passive immunization with HIV immunoglobulm. AIDS Res Hum Retroviruses 1991;7:971-3.
16. Prince AM, Horowitz B, Baker L, et al. Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV. Proc Natl Acad Sci (USA) 1988;85:6944-8.
17. Abacioglu YH, Fouts TR, Laman JD, et al. Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. AIDS Res Hum Retroviruses 1994;10:371-81.
18. Laman JD, Schellekens MM, Lewis GK, et al. A hidden region in the third variable domain of HIV-1 IIIB gp120 identified by a monoclonal antibody. AIDS Res Hum Retroviruses 1993;9:605-12.
19. Chesebro B, Wehrly K. Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J Virol 1988;62:3779-88.
20. Pincus S, Wehrly K, Chesebro B. Treatment of HIV tissue culture infection with monoclonal antibody-ricin A chain conjugates. J Immunol 1989;142:3070-5.
21. Von Brunn A, Brand M, Reichhuber C, Morys-Wortmann C, Deinhardt F, Schödel F. Principal neutralizing domain ot HIV-1 is highly immunogenic when expressed on the surface of hepatitis B core particles. Vaccine 1993;11:817-24.
22. Von Brunn A, Reichhuber C, Brand M, et al. The principal neutralizing determinant (V3) of HIV-1 induces HIV-1-neutralizing antibodies upon expression on HBcAg particles. In: Vaccines 93. Cold Spring Harbor, NY: Cold Spring Harbor Press, 1993:159-65.
23. Laman JD, Schellekens MM, Abacioglu YH, et al. Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain. J Virol 1992;66: 1823-31.
24. Ugen KE, Refaeli Y, Ziegner U, et al. Generation of monoclonal antibodies against the amino terminus of gp120 that elicit antibody-dependent cellular cytotoxicity. In: Vaccines 93. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory, 1993:215-21.
25. Moore JP, Sattentau QJ, Wyatt R, Sodroski J. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies. J Virol 1994;68:469-84.
26. Posner MR, Elboim H, Santos DS. The construction and use of a human-mouse myeloma analogue suitable for the routine production of hybridomas secreting human monoclonal antibodies. Hybridoma 1987;6:611-25.
27. Cavacini LA, Emes CL, Power J, Buchbinder A, Zolla-Pazner S, Posner MR. Human monoclonal antibodies to the V3 loop of HIV-1 gp120 mediate variable and distinct effects on binding and viral neutralization by a human monoclonal antibody to the CD4 binding site. J Acquir Immune Defic Syndr 1993;6:353-8.
28. Posner MR, Cavacini LA, Emes CL, Power J and Byrn R. Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120. J Acquir Immune Defic Syndr 1993; 6:7-14.
29. Burton DR, Barbas III CF, Persson MAA, Koenig S, Chanock RM, Lerner RA. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci USA 1991;88:10134-7.
30. Barbas III CF, Bjorling E, Chiodi F, et al. Recombinant human Fab fragments neturalize human type 1 immunodeficiency virus in vitro. Proc Natl Acad Sci USA 1992;89:9339-43.
31. Roben P, Moore JP, Thali M, Sodroski J, Barbas CF III, Burton DR. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 1994;68:4821-8.
32. Gerhard W, Yewdell J, Frankel ME, Webster R. Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. Nature 1981;290:713-7.
33. Doms RW, Earl PL, Moss B. The assembly of the HIV-1 env glycoprotein into dimers and tetramers. Adv Exp Med Biol 1991; 300:203-19.
34. Rencher SD, Slobod KS, Dawson D, Lockey TD, Hurwitz JL. Does the key to a successful HIV vaccine lie among the envelope sequences of infected individuals? AIDS Res Hum Retroviruses 1995;11:1131-3.
35. Rencher SD, Lockey TD, Srinivas RV, Owens RJ, Hurwitz JL. Eliciting HIV-1 envelope-specific antibodies with mixed vaccinia virus recombinants. Vaccine 1997;15:265-72.